Genetic polymorphisms of nerve growth factor receptor (NGFR) and the risk of Alzheimer's disease

Journal of Negative Results in BioMedicine

Volumn 11, Issue 1, 2012, Pages

  Cheng, Hui Chi ^a   Sun, Yu ^b   Lai, Liang Chuan ^c   Chen, Shih Yuan ^a   Lee, Wen Chung ^a,d   Chen, Jen Hau ^a,e   Chen, Ta Fu ^e   Chen, Hua Hsiang ^a   Wen, Li Li ^b   Yip, Ping Keung ^f   Chu, Yi Min ^f   Chen, Wei J ^a,d   Chen, Yen Ching ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b EN CHU KONG HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d Research Center for Genes Environment and Human Health   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Alzheimer's disease; haplotype; htSNP; NGFR

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGFR PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE GROWTH FACTOR RECEPTOR GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TEACHING HOSPITAL; ASIAN; CHINA; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR; VASCULAR DISEASE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NERVE GROWTH FACTOR; RISK FACTORS; VASCULAR DISEASES;

EID: 84862798301     PISSN: None     EISSN: 14775751     Source Type: Journal    
DOI: 10.1186/1477-5751-11-5     Document Type: Article

References (47)

1. Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia. 2010 http://www.alz.org/alzheimers-disease-facts-figures.asp?type=homepage
2. Dementia sufferer numbers increasing in Taiwan. http://www.etaiwannews. com/etn/news-content.php?id=970864&lang=eng-news&cate-img=49. jpg&cate-rss=news-Society-TAIWAN
3. Selective loss of central cholinergic neurons in Alzheimer's disease. Davies P, Maloney AJ, Lancet 1976 2 8000 1403 63863 (Pubitemid 8004505)
4. Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Boissiere F, Lehericy S, Strada O, Agid Y, Hirsch EC, Mol Chem Neuropathol 1996 28 1-3 219 223 10.1007/BF02815225 8871962 (Pubitemid 26275071)
5. Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Hefti F, Mash DC, Neurobiol Aging 1989 10 1 75 87 10.1016/S0197-4580(89)80014-4 2547172 (Pubitemid 19164504)
6. Nerve growth factor receptor is associated with cholinergic neurons of the basal forebrain but not the pontomesencephalon. Woolf NJ, Gould E, Butcher LL, Neuroscience 1989 30 1 143 152 10.1016/0306-4522(89)90360-6 2546097 (Pubitemid 19159803)
7. p75 and Trk: a two-receptor system. Chao MV, Hempstead BL, Trends Neurosci 1995 18 7 321 326 10.1016/0166-2236(95)93922-K 7571013
8. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Lad SP, Neet KE, Mufson EJ, Curr Drug Targets CNS Neurol Disord 2003 2 5 315 334 10.2174/1568007033482724 14529363
9. Regulation of cell survival by secreted proneurotrophins. Lee R, Kermani P, Teng KK, Hempstead BL, Science 2001 294 5548 1945 1948 10.1126/science. 1065057 11729324 (Pubitemid 33101595)
10. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. Knowles JK, Rajadas J, Nguyen TV, Yang T, LeMieux MC, Van der Griend L, Ishikawa C, Massa SM, Wyss-Coray T, Longo FM, J Neurosci 2009 29 34 10627 10637 10.1523/JNEUROSCI.0620-09.2009 19710315
11. SNPs in neurotrophin system genes and Alzheimer's disease in an Italian population. Cozza A, Melissari E, Iacopetti P, Mariotti V, Tedde A, Nacmias B, Conte A, Sorbi S, Pellegrini S, J Alzheimers Dis 2008 15 1 61 70 18780967
12. The role of impaired insulin/IGF action in primary diabetic encephalopathy. Li ZG, Zhang W, Sima AA, Brain Res 2005 1037 1-2 12 24 10.1016/j.brainres.2004.11.063 15777748 (Pubitemid 40362377)
13. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM, Neurology 1999 53 9 1937 1942 10.1212/WNL.53.9.1937 10599761
14. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A, Diabetes Care 2001 24 2 366 370 10.2337/diacare.24.2.366 11213894 (Pubitemid 32119140)
15. Increased risk of type 2 diabetes in Alzheimer disease. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC, Diabetes 2004 53 2 474 481 10.2337/diabetes.53.2.474 14747300 (Pubitemid 38174565)
16. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. Schuelke M, Mayatepek E, Inter M, Becker M, Pfeiffer E, Speer A, Hubner C, Finckh B, J Pediatr 1999 134 2 240 244 10.1016/S0022-3476(99)70424-5 9931538 (Pubitemid 29089053)
17. The Clinical Dementia Rating (CDR): current version and scoring rules. Morris J, Neurology 1993 43 11 2412 2414 8232972 (Pubitemid 23346995)
18. Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. Cataliotti A, Chen HH, Redfield MM, Burnett JC Jr, Heart Fail Clin 2006 2 3 269 276 10.1016/j.hfc.2006.09.002 17386896 (Pubitemid 44716764)
19. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, Kalaria RN, O'Brien JT, Brain 2009 132 Pt 1 195 203 19022858
20. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Pfeiffer E, J Am Geriatr Soc 1975 23 10 433 1159263
21. The structure of haplotype blocks in the human genome. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al. Science 2002 296 5576 2225 2229 10.1126/science.1069424 12029063 (Pubitemid 34680308)
22. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ, Cancer Res 2005 65 24 11771 11778 10.1158/0008-5472.CAN-05-2078 16357190 (Pubitemid 41821739)
23. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Stram DO, Leigh Pearce C, Bretsky P, Freedman M, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Thomas DC, Hum Hered 2003 55 4 179 190 10.1159/000073202 14566096 (Pubitemid 37323455)
24. A simple and efficient method for apolipoprotein E genotype determination. Chapman J, Estupinan J, Asherov A, Goldfarb LG, Neurology 1996 46 5 1484 1485 8628509 (Pubitemid 26159322)
25. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 5123 921 923 10.1126/science.8346443 8346443 (Pubitemid 23275809)
26. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, Berr C, Vidal O, Roques P, Gourlet V, et al. Hum Mol Genet 1994 3 4 569 574 10.1093/hmg/3.4.569 8069300
27. Gender differences in dementia risk factors. Azad NA, Al Bugami M, Loy-English I, Gend Med 2007 4 2 120 129 10.1016/S1550-8579(07)80026-X 17707846 (Pubitemid 47260316)
28. [Sex differences in Alzheimer's disease]. Schmidt R, Kienbacher E, Benke T, Dal-Bianco P, Delazer M, Ladurner G, Jellinger K, Marksteiner J, Ransmayr G, Schmidt H, et al. Neuropsychiatr 2008 22 1 1 15 18381051
29. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ, Ann Neurol 2004 56 4 520 531 10.1002/ana.20233 15455399 (Pubitemid 39319342)
30. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. Counts SE, Mufson EJ, J Neuropathol Exp Neurol 2005 64 4 263 272 15835262 (Pubitemid 40489553)
31. Binding of beta-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. Yaar M, Zhai S, Pilch PF, Doyle SM, Eisenhauer PB, Fine RE, Gilchrest BA, J Clin Invest 1997 100 9 2333 2340 10.1172/JCI119772 9410912 (Pubitemid 27500157)
32. Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells. Tsukamoto E, Hashimoto Y, Kanekura K, Niikura T, Aiso S, Nishimoto I, J Neurosci Res 2003 73 5 627 636 10.1002/jnr.10703 12929130 (Pubitemid 37071748)
33. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease. Coulson EJ, May LM, Sykes AM, Hamlin AS, Neuroscientist 2009 15 4 317 323 10.1177/1073858408331376 19458382
34. ProNGF, sortilin, and age-related neurodegeneration. Al-Shawi R, Hafner A, Chun S, Raza S, Crutcher K, Thrasivoulou C, Simons P, Cowen T, Ann N Y Acad Sci 2007 1119 208 215 10.1196/annals.1404.024 18056969 (Pubitemid 350191241)
35. Cognition and synaptic plasticity in diabetes mellitus. Gispen WH, Biessels GJ, Trends Neurosci 2000 23 11 542 549 10.1016/S0166-2236(00)01656-8 11074263
36. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K, Arch Intern Med 2004 164 12 1327 1333 10.1001/archinte.164.12.1327 15226167 (Pubitemid 38828884)
37. Decreased cognitive function in aging non-insulin-dependent diabetic patients. Perlmuter LC, Hakami MK, Hodgson-Harrington C, Ginsberg J, Katz J, Singer DE, Nathan DM, Am J Med 1984 77 6 1043 1048 10.1016/0002-9343(84)90186-4 6334441 (Pubitemid 15221767)
38. Insulin resistance and executive dysfunction in older persons. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, Ferrucci L, J Am Geriatr Soc 2004 52 10 1713 1718 10.1111/j.1532-5415.2004.52466.x 15450050 (Pubitemid 41709926)
39. Hyperinsulinemia and risk of Alzheimer disease. Luchsinger JA, Tang MX, Shea S, Mayeux R, Neurology 2004 63 7 1187 1192 10.1212/01.WNL.0000140292.04932. 87 15477536 (Pubitemid 39350015)
40. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Young SE, Mainous AG, Carnemolla M, Diabetes Care 2006 29 12 2688 2693 10.2337/dc06-0915 17130206 (Pubitemid 44912200)
41. Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Messier C, Gagnon M, Diabetologia 2009 52 12 2471 2474 10.1007/s00125-009-1533-2 19779694
42. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Peila R, Rodriguez BL, Launer LJ, Diabetes 2002 51 4 1256 1262 10.2337/diabetes.51.4.1256 11916953 (Pubitemid 34438377)
43. Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study. Dore GA, Elias MF, Robbins MA, Elias PK, Nagy Z, Diabetologia 2009 52 12 2551 2560 10.1007/s00125-009-1497-2 19693485
44. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ, Arch Neurol 2008 65 1 89 93 10.1001/archneurol.2007.29 18195144
45. No evidence for marked ethnic differences in accuracy of self-reported diabetes, hypertension, and hypercholesterolemia. El Fakiri F, Bruijnzeels MA, Hoes AW, J Clin Epidemiol 2007 60 12 1271 1279 10.1016/j.jclinepi.2007.02.014 17998082 (Pubitemid 350061140)
46. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, J Clin Epidemiol 2004 57 10 1096 1103 10.1016/j.jclinepi.2004.04.005 15528061 (Pubitemid 39446649)
47. Agreement between patient reports of cardiovascular disease and patient medical records. St Sauver JL, Hagen PT, Cha SS, Bagniewski SM, Mandrekar JN, Curoe AM, Rodeheffer RJ, Roger VL, Jacobsen SJ, Mayo Clin Proc 2005 80 2 203 210 10.4065/80.2.203 15704775 (Pubitemid 40194535)